Streamlined Reports and Result Interpretation
Simplified test results provide information about genomic findings and biomarkers and their associated targeted therapies when available. We also provide information on clinically relevant alterations and available clinical trial options specific to each patient’s cancer. In addition to streamlined reports, other benefits include:
A single partner for all your testing services means consistent reporting for the comparison of results across the patient journey
Reports for FoundationOne Liquid CDx include historic patient findings from earlier FoundationOne tests, which allow you to follow your patients’ genomic profiles across the duration of their diseases
List of FDA-approved companion diagnostics, if available, to identify patients who may be eligible for treatment with associated therapies
This section appears when patients may be resistant to therapy based on their genomic profile
Medical Case Consulting
Discuss patient results with our team of oncologists and pathologists. This robust on-call program is covered by physicians and Medical Science Liaisons (MSLs) within Foundation Medicine or by external oncologists who are subject matter experts and consultants for Foundation Medicine.
Inquiries can be escalated via phone, email, or through the “Ask an Expert” portal
More than 100 inquiries per month are submitted and addressed successfully*
Inquiries are handled within 24-48 hours in 95% of cases*
We’re Here to Help
Questions? Our Client Services team is on hand to help.
*As of October 2019.
†On FoundationOne Liquid CDx, MSI status will be reported for samples determined to have high microsatellite instability.
Important Safety Information
FoundationOne Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.